Bart de Laat

Bart de Laat

Auto-generated profile, based on publicly available information

Bart de Laat

Department of Radiology and Biomedical Imaging, Yale University, New Haven, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
BLBart de Laat
Bart de Laat
JHJocelyn Hoye
Jocelyn Hoye
GSGelsina Stanley
Gelsina Stanley
MHMichelle Hespeler
Michelle Hespeler
JLJennifer Ligi
Jennifer Ligi
STSule Tinaz
Sule Tinaz
Parkinson’s disease (PD) is characterized by a progressive loss of dopaminergic neurons. Exercise has been reported to slow the clinical progression of PD. We evaluated the dopaminergic system of patients with mild and early PD before and after a six-month program of intense exercise. Using18F-FE-PE2I PET imaging, we measured dopamine transporter (DAT) availability in the striatum and substantia nigra. Using NM-MRI, we evaluated the neuromelanin content in the substantia nigra. Exercise reversed the expected decrease in DAT availability into a significant increase in both the substantia nigra and putamen. Exercise also reversed the expected decrease in neuromelanin concentration in the substantia nigra into a significant increase. These findings suggest improved functionality in the remaining dopaminergic neurons after exercise. Further research is needed to validate our findings and to pinpoint the source of any true neuromodulatory and neuroprotective effects of exercise in PD in large clinical trials.

1 December 2019 in Biological Psychiatry
Verified
Journal Article
Open access
BLBart de Laat
Bart de Laat
AGAlissa Goldberg
Alissa Goldberg
JSJulia Shi
Julia Shi
JTJeanette M. Tetrault
Jeanette M. Tetrault
NNNabeel Nabulsi
Nabeel Nabulsi
SKSuchitra Krishnan-Sarin
Suchitra Krishnan-Sarin
Naltrexone is a nonselective opioid receptor antagonist used as a treatment for alcohol use disorder. However, only modest clinical effects have been observed, possibly because of limited knowledge about the biological variables affecting the efficacy of naltrexone. We investigated the potential role of the kappa opioid receptor (KOR) in the therapeutic effect of naltrexone. A total of 48 non-treatment-seeking heavy drinkers (16 women) who met DSM-IV criteria for alcohol dependence participated in two alcohol drinking paradigms (ADPs) separated by a week of open-label naltrexone (100 mg daily). Craving, assessed with the Alcohol Urge Questionnaire and the Yale Craving Scale, and drinking behavior were recorded in each ADP. Prior to naltrexone initiation, KOR availability was determined in the amygdala, hippocampus, pallidum, striatum, cingulate cortex, and prefrontal cortex using positron emission tomography with [11C]LY2795050. Participants reported lower levels of craving (Yale Craving Scale: -11 ± 1, p < .0001; Alcohol Urge Questionnaire: -6 ± 0.6, p < .0001) and consumed fewer drinks (-3.7 ± 4, p < .0001) during the second ADP following naltrexone therapy. The observed reduction in drinking was negatively associated with baseline KOR availability in the striatum (p = .005), pallidum (p = .023), and cingulate cortex (p = .018). Voxelwise analysis identified clusters in the bilateral insula, prefrontal, and cingulate cortex associated with the reduction in drinking (p < .0001). In addition, KOR availability in all evaluated brain regions was associated with craving measured in both ADPs. The KOR is implicated in drinking and craving following naltrexone therapy in alcohol use disorder.

15 June 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
BLBart de Laat
Bart de Laat
NNNabeel Nabulsi
Nabeel Nabulsi
YHYiyun Huang
Yiyun Huang
SOStephanie S. O’malley
Stephanie S. O’malley
JFJanice C. Froehlich
Janice C. Froehlich
SKSuchitra Krishnan-Sarin
Suchitra Krishnan-Sarin

23 May 2018 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
BLBart de Laat
Bart de Laat
AWAkila Weerasekera
Akila Weerasekera
GLGil Leurquin‐Sterk
Gil Leurquin‐Sterk
WGWilly Gsell
Willy Gsell
GBGuy Bormans
Guy Bormans
KLKoen Van Laere
Koen Van Laere

13 October 2020 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
PDF file
BLBart de Laat
Bart de Laat
EMEvan D. Morris
Evan D. Morris
For radioligands without a reference region, the Lassen plot can be used to estimate receptor occupancy by an exogenous drug ([ ]). However, the Lassen plot is not well-suited for spatial variation in [ ]. To overcome this limitation, we introduce a Lassen plot filter, i.e. a Lassen plot applied to local neighborhoods in PET images. Image data were simulated with regional variation in [ ], [ ], both, or neither and analyzed using the change in binding potential ([ ]), the conventional Lassen plot, and the Lassen plot filter at the region of interest (ROI) and voxel level. All methods were also applied to a human [11C]flumazenil occupancy study using PF-06372865. This combination of a non-selective radioligand and selective drug should lead to varying [ ]provided the distribution of subtypes varies spatially. In contrast with [ ] and the conventional Lassen plot, ROI-level and voxel-level Lassen plot filter estimates remained unbiased in the presence of regional variation in [ ] or [ ]. In the [11C]flumazenil data-set, [ ] was shown to vary regionally in accordance with the distribution of binding sites for [11C]flumazenil and PF-06372865. We demonstrate that a local-neighborhood Lassen plot filter provides robust and unbiased estimates of [ ] and [ ] without the need for any user intervention.

24 June 2022 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
BLBart de Laat
Bart de Laat
NNNabeel Nabulsi
Nabeel Nabulsi
YHYiyun Huang
Yiyun Huang
SOStephanie S. O'Malley
Stephanie S. O'Malley
EMEvan D. Morris
Evan D. Morris
SKSuchitra Krishnan‐Sarin
Suchitra Krishnan‐Sarin